National Procedure (NP) - Overview
If an applicant aims to procure a Marketing Authorization (MA) in a chosen European Union (EU) member state, it is required to submit a Market Authorization Application (MAA) to the respective state’s competent authority through the National Procedure (NP).
The competent authority is responsible for reviewing and granting an MA. Most of the Health Authorities (HAs) require two hundred and ten (210) days for the review and approval of MAA. However, it may vary slightly from one HA to the other, based on the member states, followed by the national phase for translation activities.
If an MA is granted by the competent authority of the EU member state and the applicant would like to register the medicinal product in any other EU member states, the MA holder can file the same MAA to the required state (which will be referred to as Concern Member State [CMS]), and the member state who authorized the MAA shall be considered as the Reference Member State (RMS).
With an expertise in dealing with Article 10(1) submissions to HAs in the EU, Freyr extends end-to-end submissions support for all the procedures, including the National Procedure (NP). Further, Freyr supports manufacturers in appointing Qualified Person (QP) for quality and QP for Pharmacovigilance (QPPV) in the respective member states to validate quality and organize post-market surveillance.
National Procedure (NP) - Expertise
- Legal representation as a Marketing Authorization Holder (MAH) for the medicinal product manufacturers who do not have establishments in the European Economic Area (EEA).
- Regulatory consultation/strategic support during the development stage of the medicinal products.
- Support in selection of dissolution parameters/multimedia/for performance of dissolution for test product and Reference Medicinal Product (RMP).
- Preparation of Product Development Report (discriminatory nature of media).
- Designing specifications (finished product/API/in-process/intermediates).
- Advice in the selection of Regulatory submission procedure based on the MAH’s requirements.
- Pre-submission administrative activities.
- Advice for appointment/consultation of Qualified Person (QP) for quality and Qualified Person for Pharmacovigilance (QPPV) (if applicant’s office is not in EEA and they do not have their own QP and QPPV).
- Advice for consultation of batch release testing site and batch control site testing (if applicants do not have their own site in EEA).
- Regulatory assessment/gap-analysis of source documents/already registered dossier for their Regulatory adequacy.
- Compiling, technical reviewing, finalizing, publishing, and submission of the MAA to the EU HAs.
- Regulatory strategy in the responses to HA queries (RTQs).
- Prepare response to HA queries (HAQs) with supporting documents/data with scientific rationale to avoid delay in approval.
- Evaluation of change controls and supporting documents.
- Preparation of variation submission strategy.
- Compilation and submissions of variations and renewals to the MAA.
- Tracking of renewal submissions for the MAA in the EU.
- Follow-up with Regulatory agencies for the approval of the MAA.
